Replimune Group (NASDAQ:REPL) Shares Up 9.5% – Should You Buy?

Replimune Group, Inc. (NASDAQ:REPL)’s share price shot up 9.5% during trading on Thursday . The stock traded as high as $13.56 and last traded at $13.26. 518,051 shares changed hands during trading, a decline of 50% from the average session volume of 1,040,285 shares. The stock had previously closed at $12.11.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on REPL. Jefferies Financial Group lifted their target price on Replimune Group from $16.00 to $19.00 and gave the stock a “buy” rating in a report on Wednesday, December 4th. JPMorgan Chase & Co. lifted their price objective on Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a report on Tuesday, September 24th. HC Wainwright reissued a “buy” rating and set a $17.00 target price on shares of Replimune Group in a research note on Friday, November 22nd. Finally, BMO Capital Markets raised their price objective on shares of Replimune Group from $14.00 to $18.00 and gave the stock an “outperform” rating in a report on Friday, November 22nd. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Replimune Group has a consensus rating of “Buy” and an average price target of $17.29.

Replimune Group Trading Up 4.7 %

The company has a debt-to-equity ratio of 0.18, a current ratio of 10.11 and a quick ratio of 10.11. The business’s 50-day moving average is $12.41 and its two-hundred day moving average is $10.96. The firm has a market cap of $867.53 million, a P/E ratio of -4.16 and a beta of 1.26.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.07. As a group, analysts predict that Replimune Group, Inc. will post -2.91 earnings per share for the current fiscal year.

Insider Transactions at Replimune Group

In other Replimune Group news, insider Konstantinos Xynos sold 7,246 shares of the firm’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $10.78, for a total transaction of $78,111.88. Following the completion of the sale, the insider now owns 109,885 shares of the company’s stock, valued at $1,184,560.30. This trade represents a 6.19 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Sushil Patel sold 10,000 shares of the company’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $12.42, for a total transaction of $124,200.00. Following the completion of the transaction, the chief executive officer now owns 202,014 shares in the company, valued at approximately $2,509,013.88. This represents a 4.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 8.80% of the stock is owned by company insiders.

Institutional Trading of Replimune Group

Several institutional investors have recently added to or reduced their stakes in the company. Baker BROS. Advisors LP boosted its holdings in Replimune Group by 10.0% in the 3rd quarter. Baker BROS. Advisors LP now owns 11,045,336 shares of the company’s stock valued at $121,057,000 after purchasing an additional 1,000,000 shares during the period. Millennium Management LLC boosted its stake in shares of Replimune Group by 575.1% in the second quarter. Millennium Management LLC now owns 3,118,035 shares of the company’s stock valued at $28,062,000 after buying an additional 2,656,173 shares during the period. Braidwell LP grew its position in Replimune Group by 203.0% during the third quarter. Braidwell LP now owns 3,070,837 shares of the company’s stock worth $33,656,000 after buying an additional 2,057,460 shares in the last quarter. State Street Corp increased its stake in Replimune Group by 102.1% during the 3rd quarter. State Street Corp now owns 2,340,042 shares of the company’s stock worth $25,647,000 after acquiring an additional 1,182,181 shares during the period. Finally, Geode Capital Management LLC raised its holdings in Replimune Group by 17.9% in the 3rd quarter. Geode Capital Management LLC now owns 1,428,301 shares of the company’s stock valued at $15,657,000 after acquiring an additional 217,308 shares in the last quarter. 92.53% of the stock is currently owned by institutional investors.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.